{"schema_version":"secwatch.filing_event.v1","accession":"0001420720-26-000019","form_type":"8-K","ticker":"IBIO","cik":"0001420720","company_name":"iBio, Inc.","filed_at":"2026-08-28T12:30:48+00:00","discovered_at":"2026-08-28T12:35:17.372674+00:00","generated_at":"2026-08-28T12:35:24.994960+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"iBio FY2026: cash $88M, R&D up to $19.6M, IBIO-600 Phase 1 on track","bullets":["Revenue $0.1M (down from $0.4M); R&D expenses $19.6M vs $8.3M; G&A $10.6M.","Cash and investments $88.0M as of June 30, 2026; runway extended into FY2028.","IBIO-600 Phase 1 dosed 31 of 32 participants; advancing to multiple ascending dose.","IBIO-610 and IBIO-800 in IND-enabling studies; in-licensed AstralBio amylin receptor program.","Financings: $100M public offering (Aug 2025), $26M private placement (Jan 2026), $100M ATM with Jefferies."],"urls":{"canonical":"https://secwatch.observer/filing/0001420720-26-000019","json":"https://secwatch.observer/filing/0001420720-26-000019.json","markdown":"https://secwatch.observer/filing/0001420720-26-000019.md","text":"https://secwatch.observer/filing/0001420720-26-000019.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1420720/000142072026000019/0001420720-26-000019-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1420720/000142072026000019/ibio-20260828x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-28T12:35:24.994960+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}